<?xml version="1.0" encoding="UTF-8"?>
<p>Corticosteroids, the mainstay for the treatment of many immune-mediated diseases, have been associated with worse outcomes in influenza pneumonia
 <sup>
  <xref rid="CIT0075" ref-type="bibr">75</xref>
 </sup> and with a reduction of viral clearance in patients with SARS
 <sup>
  <xref rid="CIT0076" ref-type="bibr">76</xref>
 </sup> and MERS.
 <sup>
  <xref rid="CIT0077" ref-type="bibr">77</xref>
 </sup> Current evidences seem to point against their use in COVID-19, as their administration was associated with higher mortality, longer hospitalizations, and a higher risk for secondary bacterial infections.
 <sup>
  <xref rid="CIT0078" ref-type="bibr">78</xref>
 </sup> Furthermore, the SECURE-IBD study showed that systemic corticosteroids significantly increased the risk for hospitalization, need for intensive care, and death.
 <sup>
  <xref rid="CIT0074" ref-type="bibr">74</xref>
 </sup> Consequently, steroid prescription should be cautiously weighted in non-COVID-19 patients, and prednisone â‰¥20 mg/day should be avoided.
 <sup>
  <xref rid="CIT0079" ref-type="bibr">79</xref>
 </sup>
</p>
